Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study Background: To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid.
Background: To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid.
Patients and methods: A phase 3 trial comparing tamoxifen, letrozole or letrozole + zoledronic acid in patients with hormone receptor-positive early breast cancer was conducted; triptorelin was given to premenopausal patients. Two comparisons were planned: letrozole versus tamoxifen and letrozole + zoledronic acid versus letrozole. Primary end point was the difference in 1-year change of T-score at lumbar spine (LTS) measured by dual energy X-ray absorptiometry scan.
Results: Out of 483 patients enrolled, 459 were available for primary analyses. Median age was 50 (range . The estimated mean difference (95% confidence interval [CI] ) in 1-year change of LTS was equal to −0.30 (95% CI −0.44 to −0.17) in the letrozole versus tamoxifen comparison (P < 0.0001) and to +0.60 (95% CI +0.46 to +0.77) in the letrozole + zoledronic acid versus letrozole comparison (P < 0.0001). Bone damage by letrozole decreased with increasing baseline body mass index in premenopausal, but not postmenopausal, patients (interaction test P = 0.004 and 0.47, respectively).
Conclusions:
In the HOBOE (HOrmonal BOne Effects) trial, the positive effect of zoledronic acid on BMD largely counteracts damage produced by letrozole as compared with tamoxifen. Letrozole effect is lower among overweight/ obese premenopausal patients. Key words: adjuvant hormonal treatment, body mass index, bone mineral density, breast cancer, phase 3 randomized trial, zoledronic acid introduction Tamoxifen has been for a long time the unique standard adjuvant hormonal treatment of patients with hormone receptor-positive early breast cancer [1, 2] .
In the last decade, clinical trials have consistently demonstrated that aromatase inhibitors (AI), anastrozole, letrozole and exemestane, improve the efficacy of treatment in postmenopausal patients [3] . Whether AI may increase the efficacy of treatment also in premenopausal patients is not yet known; the results with anastrozole are negative [4] .
Side-effects of AI are mostly due to suppression of estradiol levels, direct consequence of their mechanism of action; a frequent side-effect is the reduction of bone mineral density (BMD), with increasing occurrence of osteoporosis and bone fractures [5] . Bisphosphonates counteract bone resorption and their use has been recently advised for patients with specific risk factors or starting AI with some degree of osteopenia [6] . Zoledronic acid is a nitrogen-containing bisphosphonate that has shown higher potency as compared with other compounds of the same class, and it can counteract bone loss produced by estradiol suppression [7] .
In 2004, we started the HOBOE (HOrmonal BOne Effects) study to estimate the negative effect on bone of letrozole compared with tamoxifen and the positive effect of the addition of zoledronic acid to letrozole, in pre-and postmenopausal patients with hormone receptor-positive early breast cancer. As far as we know, only Gnant et al. [8] directly dealt with the two questions in the same trial, in premenopausal patients only and using anastrozole as AI.
patients and methods
The randomized phase 3 HOBOE trial (NCT00412022) compared the bone effects of adjuvant tamoxifen, letrozole or letrozole + zoledronic acid in patients with hormone receptor-positive early breast cancer. It was promoted independently by the investigators; planned as a single center (NCI Napoli) study, it has been subsequently amended to allow other centers to participate; it was approved by the Independent Ethical Committees of all participating institutions.
patient selection
Patients, at least 18 years old, with histologically confirmed breast cancer, either pre-or postmenopausal, without evidence of recurrence after eventual adjuvant chemotherapy, whose tumor expressed estrogen or progesterone receptors in at least 1% of tumor cells at immunohistochemistry (according to 2001 St Gallen Criteria [9] ) were eligible if they were not pregnant or lactating, had normal kidney and liver function, had no evidence of active bone fracture, had not assumed steroids on a regular basis in the previous 12 months, nor had they assumed drugs interfering with bone metabolism (e.g. calcitonin, mitramycin) in the previous 2 weeks. Patients treated by or requiring invasive therapeutic procedures for dental diseases and those who had previously received tamoxifen or an AI were not eligible. Previous adjuvant chemotherapy was allowed as well as adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive tumors. If indicated, adjuvant radiotherapy could be carried out, before or after randomization, also concurrently with study treatments. There were no exclusion criteria based on baseline bone status. All the patients signed written informed consent. Patients were pragmatically considered as premenopausal if the date of their last menses was within 1 year before randomization; thanks to this definition, possibly all patients with chemotherapy-induced suppression of ovarian function received triptorelin.
treatment
Patients were randomly allocated to receive tamoxifen 20 mg/day for 5 years if premenopausal, or for 2 years followed by an AI at standard dose for 3 years if postmenopausal, or letrozole 2.5 mg/day for 5 years, or letrozole plus zoledronic acid 4 mg i.v. every 6 months for 5 years, starting at the beginning of the hormonal treatment. In premenopausal patients, triptorelin 3.75 mg, i.m. every 4 weeks for 5 years (or up to the age of 55), was added to the treatment in all the three arms. Dose of zoledronic acid was adjusted according to creatinine clearance (CrCl): 4 mg (full dose) for CrCl ≥ 60 ml/min, 3.5 mg for 50 ≤ CrCl < 60 ml/min, 3.3 mg for 40 ≤ CrCl < 50 ml/min, 3.0 mg for 30 ≤ CrCl <40 ml/min. Calcium and vitamin D were commonly prescribed to patients with osteoporosis or severe osteopenia (T-score < −2); their use, however, was not dictated by the protocol and data were not collected.
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Two comparisons were planned a priori: (i) letrozole versus tamoxifen, to estimate the reduction of BMD expected by letrozole and (ii) letrozole + zoledronic acid versus letrozole, to assess whether and how much zoledronic acid was able to counteract such effect. For each comparison, sample size was calculated to detect an effect of small-medium size (35% of standard deviation [SD]), with two-tailed alpha error = 0.025 and power = 80%; 157 patients per arm (471 overall) were required.
Two additional unplanned secondary analyses, prompted by intervening findings of the literature [10] [11] [12] [13] , were carried out to assess (i) whether baseline body mass index (BMI) predicted bone effects of letrozole as compared with tamoxifen and (ii) whether the level of estradiol suppression at 6 months predicted bone effects of letrozole at 1 year as compared with tamoxifen. To allow indirect comparison with literature findings, these analyses were scattered by menopausal status and patients in the letrozole + zoledronic acid arm were excluded to avoid the confounding effect of zoledronic acid.
end points
The primary study end point was the change of lumbar spine T-score (LTS), measured by dual energy X-ray absorptiometry (DXA), 1 year after randomization. T-score is the number of SDs a patient's BMD differs from that of a healthy young adult of the same gender and ethnicity; lower scores indicate lower bone density. T-score was preferred to BMD (g/cm 2 ) because it is commonly used in clinical practice to define bone health status. DXA was made by a GE scanner (Lunar DPX, Madison, WI), daily calibrated using the same bone density phantom provided by the manufacturer. BMD was measured at lumbar spine (L2-L4) and femoral necks, blinded to treatment assignment. The images were evaluated for possible artifacts (i.e. surgical clips, metal zipper, coin, etc.), and/or local structural bone changes (i.e. osteophytes, aortic calcification, etc.). The radiation dose for each individual study, with this method, was <0.1 μGy.
The coefficient of variation of BMD, in normal subjects, was 1.5% and 2% at the hip and lumbar spine, respectively. According to the World Health Organization criteria, bone status was categorized as normal if the worst T-score among lumbar spine and femoral necks was >−1, osteopenia if T-score ranged from −2.5 to −1, osteoporosis if T-score was <−2.5 [14] . Plasma levels of estradiol-17β were measured before randomization and after 6 and 12 months. All the tests were done at NCI Napoli by means of ECLIA (electrochemiluminescence immunoassay; Roche Diagnostics GmbH, Mannheim, Germany), a competitive test using a polyclonal antibody specifically directed against estradiol-17β. The lowest detection limit of the test is 5 pg/ml and represents the lowest analyte level that cannot be distinguished from 0; 12 pg/ml is indicated by the manufacturer as the lowest analyte level that can be measured with a variation coefficient ≤20%. According to these two limits, three categories of estradiol levels were defined: <5, 5-11.9, ≥12 pg/ml. The laboratory performance is periodically checked within the EQAS-CNR (External Quality Assessment Schemes-National Research Council) program (www.eqas.cnr.it).
Toxicity was coded according to National Cancer Institute-Common Toxicity Criteria (NCI-CTC), version 2.0. The worst grade of toxicity reported within 1 year from randomization was used for the present analysis.
randomization Patients were randomly allocated 1 :1 :1 through a computerized procedure of minimization centralized at the Clinical Trials Unit of NCI Napoli; with center, menopausal status ( pre, post), baseline bone status (normal, osteopenia, osteoporosis), previous chemotherapy (yes, no), pT and pN as strata.
statistical analysis
Statistical analysis was based on intention to treat. For each primary comparison, 1-year changes of LTS were depicted by box and whiskers plots and tested using a multivariable linear regression model adjusted by age, menopausal status, previous chemotherapy and baseline LTS as covariates. Center was not considered as a covariate because 452 out of 459 patients were enrolled at the same center. The chi-square test was applied to compare rates of patients with worsening bone status among treatment arms.
Possible differences of letrozole bone effect according to baseline BMI or 6-month estradiol suppression were assessed separately for pre-and postmenopausal patients; interaction with treatment was tested in a linear regression model that included age, previous chemotherapy, baseline LTS and baseline BMI (or alternatively baseline estradiol) as covariates.
results

patients' flow
From March 2004 to December 2009, 483 patients were randomly assigned; 24 patients were excluded from the analyses because they did not perform any post-treatment DXA scan. Of the 459 patients available for BMD analysis, 22 stopped their adjuvant treatment before 1 year, 14 because of toxicity, 6 because of breast cancer recurrence and 2 for refusal; these patients, however, were included in the analyses according to the intention-to-treat principle (supplemental Figure S1 , available at Annals of Oncology online).
baseline characteristics
Baseline characteristics of patients, reported in Table 1 , were balanced among treatment arms. Compared with premenopausal women, postmenopausal women had significantly lower baseline values of lumbar and femoral T-score, had more frequently osteopenia or osteoporosis, had higher baseline BMI values, were more frequently obese and had lower baseline estradiol levels ( Table 2) .
treatment toxicity
No unexpected difference in toxic events among the arms was observed in the first year of treatment. There was no grade 5 and only one grade 4 event (heart ischemia in the letrozole + zoledronic acid arm). There was no bone fracture. Patients in the letrozole arm suffered significantly more hypercholesterolemia and muscle or skeletal events (arthritis or bone or muscle pain) than those in the tamoxifen arm. Women in the letrozole + zoledronic acid arm had significantly more fever than those in the letrozole arm. There was no case of osteonecrosis of the jaw. Details of toxicity are reported in the supplemental Table S1 (available at Annals of Oncology online).
primary analysis
Mean (SD) change in LTS was −0.27 (0.63) with tamoxifen, −0.57 (0.66) with letrozole and +0.02 (0.59) with letrozole + zoledronic acid; the estimated mean differences (95% confidence interval [CI]) of changes from baseline were equal to -0.30 (95% CI −0.44 to −0.17) in the letrozole versus tamoxifen comparison and +0.60 (95% CI +0.46 to +0.77) in the letrozole + zoledronic acid versus letrozole comparison. Both differences were highly statistically significant (P < 0.0001). Differences between treatment arms were in the same direction both in the pre-and postmenopausal subgroups (Figure 1) . Variations of bone status between baseline and 1-year scan by arm are reported in supplemental Table S2 (available at Annals of Oncology online). Overall, patients worsened more frequently with letrozole (35/149, 23.5%) than with tamoxifen (18/156, 11.5%) or letrozole + zoledronic acid (14/154, 9.1%). P values were equal to 0.01 and 0.003 for letrozole versus tamoxifen and letrozole + zoledronic acid versus letrozole comparisons, respectively.
correlation of letrozole effect with BMI
Among premenopausal patients (Figure 2, top) , bone effect of letrozole compared with tamoxifen was clearly observed only within the subgroup with normal weight at baseline but disappeared in overweight or obese patients (interaction test P = 0.004, adjusted by age, previous chemotherapy, baseline LTS and baseline BMI as covariates). Conversely, among postmenopausal patients (Figure 2 , bottom) differences in LTS changes were observed across all BMI subgroups (interaction test P = 0.47, adjusted as above).
correlation of letrozole effect with estradiol suppression
After 6 months of treatment, estradiol levels were more frequently suppressed among patients receiving letrozole than among those receiving tamoxifen (P < 0.0001). Estradiol was undetectable in 46.8% of patients receiving letrozole, as compared with 23.7% of those receiving tamoxifen; however, ∼20% of patients receiving letrozole, either pre-or postmenopausal, still had estradiol over the upper threshold of 12 pg/ml ( Table 3) . As a check, a similar proportion (18.3%) was observed in the letrozole + zoledronic acid arm. As shown in Figure 3 , 1-year LTS changes were not affected by the level of estradiol suppression at 6 months, both in premenopausal (interaction test P = 0.31) and in postmenopausal patients (interaction test P = 0.22).
discussion
The design of the HOBOE trial is unique since it allowed a direct comparison of the size of the two effects in both preand postmenopausal women; profound differences, indeed, were found between the two subgroups for bone metabolism, BMI and estradiol levels, which cannot be seen in trials involving to either pre-or postmenopausal patients only. For instance, Gnant et al. [8] also dealt with the two questions in original articles Annals of Oncology the same trial but in premenopausal patients only and using anastrozole as AI. Furthermore, heterogeneity between centers was reduced by substantially performing the trial in a single Institution and using the same machinery over the time for the assessment of the primary end point. However, this design also led to a low enrollment rate as a drawback. We confirmed that (i) adjuvant letrozole significantly reduces BMD in comparison with tamoxifen, consistently with previous studies [15] [16] [17] [18] [19] , and (ii) zoledronic acid added to letrozole significantly increases BMD in comparison with letrozole alone, as already reported in the literature [8, [20] [21] [22] [23] [24] . In addition, we found that the size of the positive effect of zoledronic acid at 1 year counteracts the negative effect of letrozole and that this effect is substantially similar both in preand postmenopausal women. Such impressive result at 1 year follows from just two administrations of zoledronic acid (after randomization and 6 months later); therefore, it would seem reasonable to explore whether longer intervals (e.g. yearly), or a lower number of administrations, or a lower dosage per administration might be effective as well, with less side-effects and costs. Clearly, things would change if the claimed anticancer effect of zoledronic acid in early breast cancer [4, [25] [26] [27] would be definitely accepted.
Following the literature [10] [11] [12] [13] , we also tested two questions previously unplanned. First, we found that the bone effect of letrozole according to BMI categories differed between preand postmenopausal women. The decreasing effect with increasing values of BMI in premenopausal patients could be expected since fat tissue is the major repository of aromatase, and fixed doses of letrozole could fail to fully inhibit the target in excess. These data are likely consistent with the findings of the ABCSG12 study [10] , where higher BMI values were correlated with lack of anticancer efficacy of anastrozole; however, caution is required because bone effects might be unrelated to anticancer efficacy. Conversely, we found that BMI did not affect bone effects of letrozole among postmenopausal women. Although we cannot exclude the play of chance, we might hypothesize that lower baseline values of estradiol in postmenopausal patients could make their bone more akin to damage even among overweight or obese patients.
The second unplanned finding of the HOBOE trial was that estradiol suppression during treatment with letrozole was less frequent and profound than expected. At 6 months, indeed, 
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∼50% of the patients had undetectable estradiol levels, but 20% had values higher than the upper threshold of 12 pg/ml. The latter value is quite high, even assuming low specificity of the test in the range of low values; therefore, our findings strongly suggest that in clinical practice, estradiol suppression with AI might be less complete than expected on the basis of preclinical and early clinical studies. These findings, if confirmed, might be extremely important because estradiol suppression is the only known mechanism of action for anticancer effect of AI, and it is known that breast cancer cells can be stimulated by very low amount of estradiol because of the changes of estrogen receptor sensitivity, which ultimately bring to endocrine resistance [28] . It would be interesting to verify whether monitoring of estradiol suppression might be useful to identify patients who do not benefit from these drugs. Although we did not find a significant interaction between letrozole bone effects and estradiol levels at 6 months, we cannot exclude that lack of suppression might still play a role in the anticancer effect.
Testing the predictive value of the 6-month value only could be a limit of our study. We did it for two reasons: first, the baseline estradiol levels could be affected by previous chemotherapy, which was assumed by two-thirds of our patients; second, the dynamic of estradiol changes from baseline to 6 months could not be calculated because of sensitivity limits of the method. Therefore, we cannot rule out that some interaction between estradiol reduction and bone damage induced by letrozole might exist. The development of analytical methods with higher accuracy for low estradiol levels would be important to address this issue.
In conclusion, the HOBOE study proves that the addition to letrozole of zoledronic acid produces an increase of BMD that largely overcomes the negative effect of letrozole as compared with tamoxifen. In addition, the study suggests (i) that letrozole effect might be reduced among overweight or obese premenopausal patients and (ii) that further investigations are needed to assess whether lack of complete estradiol suppression might be a predictive marker for anticancer 
